Shaygannejad Vahid, Montazeri Saeed, Jamshidian Azam, Tahani Soheil, Gharagozloo Marjan, Ashtari Fereshteh, Vesal Sahar, Hasheminia Seyed Javad, Dehghani Leila
Department of Neurology and Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 81745-319, Iran, e-mail:
Iran J Immunol. 2014 Jun;11(2):134-8.
Midkine (MK) is a heparin-binding growth factor with promoting effects in inflammatory responses through enhancing leukocytes migration.
To study the correlation between MK serum levels and concentration of inflammatory cytokines in Multiple Sclerosis (MS) patients.
We evaluated the MK level and its relationship with inflammatory cytokines (IL-17 and IL-23) and anti-inflammatory ones (IL-10 and TGF-β) in multiple sclerosis (MS) patients. The serum concentrations of MK and cytokines were assessed by ELISA in 32 MS patients in comparison with 32 healthy subjects.
Our data showed that the MK concentration in MS patients is lower than healthy controls (341.15 ± 40.71 Pg/ml vs. 620.15 ± 98.61 Pg/ml, respectively, p=0.015). We also observed a significant decrease in IL-10, IL-23, and TGF-β cytokine levels in MS patients. There was a significant correlation between MK and IL-23 concentrations in our study (r = +0.829, p≤ 0.001).
These results confirm a role for MK in inflammatory reactions in MS.
中期因子（MK）是一种肝素结合生长因子，通过增强白细胞迁移对炎症反应具有促进作用。
研究多发性硬化症（MS）患者血清MK水平与炎性细胞因子浓度之间的相关性。
我们评估了多发性硬化症（MS）患者的MK水平及其与炎性细胞因子（IL-17和IL-23）和抗炎细胞因子（IL-10和转化生长因子-β）的关系。通过酶联免疫吸附测定法（ELISA）评估了32例MS患者与32例健康受试者血清中MK和细胞因子的浓度。
我们的数据显示，MS患者的MK浓度低于健康对照组（分别为341.15±40.71皮克/毫升和620.15±98.61皮克/毫升，p = 0.015）。我们还观察到MS患者的IL-10、IL-23和转化生长因子-β细胞因子水平显著降低。在我们的研究中，MK与IL-23浓度之间存在显著相关性（r = +0.829，p≤0.001）。
这些结果证实了MK在MS炎症反应中的作用。
